Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
NCT02997761Phase 2Completed
- Sponsor
- University of California, Davis
- Start
- Jun 2017
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of California, Davis. Started Jun 2017; status: completed.
02
Drugs
ibrutinibblinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02997761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997761.